Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537, on the TrumpRx website.

The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...

Earlier this year, when the administration proposed deep cuts to the National Institutes of Health, lawmakers from both parties swiftly and rightly pushed back. Slashing medical research funding, they ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future. With the launch of TrumpRx earlier this year, Americans got their first taste of how ...

Sweeping health policy changes, from volatile drug tariffs to Medicare price negotiations, are colliding with legal disputes and political maneuvering ahead of the 2026 midterms. Federal agency ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...

The Trump administration released its 2026 Economic Report this week, outlining achievements from the past year and goals for ...

The Trump administration’s announcement of the first MFN agreement is a major drug pricing policy milestone. Industry and policymakers await the release of the administration’s Global Benchmark for ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...